Correlation between body mass index and leucopenia after administration of valganciclovir for cytomegalovirus infection in Chinese cardiac recipients

I. Ming Chen, Hsiao Huang Chang, Chiao Po Hsu, Shiau Ting Lai, Yuan Chen Hsieh, Chun Che Shih

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background: Valganciclovir (VGC) has recently been proved efficacious for the prophylaxis and treatment of cytomegalovirus (CMV) infection in transplant recipients. Leucopenia is a troublesome complication of VGC but the possible risk factors are unknown. Methods and Results: Once a cardiac recipient's quantitative real-time CMV-polymerase chain reaction result showed positive, VGC was administered for 3 months. The 61 cardiac recipients enrolled in this study were divided into 2 groups: non-leucopenia group (n=29) and leucopenia group (n=32). The white blood cell (WBC) counts in the leucopenia group dropped approximately 55.6% in the first month after VGC therapy (pre-VGC WBC count: 5,544 cells/mm3 vs post-VGC WBC count: 2,460 cells/mm3, p<0.0001). The most significant difference between the 2 groups was body mass index (BMI, 23.04 vs 25.84, p=0.008), which was the impact factor of VGC-induced leucopenia. Conclusion: Severe leucopenia may develop after VGC therapy in Chinese cardiac recipients, especially those with lower BMI.

Original languageEnglish
Pages (from-to)968-972
Number of pages5
JournalCirculation Journal
Volume71
Issue number6
DOIs
Publication statusPublished - Jun 4 2007
Externally publishedYes

Fingerprint

Leukopenia
Cytomegalovirus Infections
Body Mass Index
Leukocyte Count
valganciclovir
Cytomegalovirus
Real-Time Polymerase Chain Reaction
Therapeutics

Keywords

  • Cardiac transplant
  • Cytomegalovirus
  • Leucopenia
  • Valganciclovir

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Correlation between body mass index and leucopenia after administration of valganciclovir for cytomegalovirus infection in Chinese cardiac recipients. / Chen, I. Ming; Chang, Hsiao Huang; Hsu, Chiao Po; Lai, Shiau Ting; Hsieh, Yuan Chen; Shih, Chun Che.

In: Circulation Journal, Vol. 71, No. 6, 04.06.2007, p. 968-972.

Research output: Contribution to journalArticle

Chen, I. Ming ; Chang, Hsiao Huang ; Hsu, Chiao Po ; Lai, Shiau Ting ; Hsieh, Yuan Chen ; Shih, Chun Che. / Correlation between body mass index and leucopenia after administration of valganciclovir for cytomegalovirus infection in Chinese cardiac recipients. In: Circulation Journal. 2007 ; Vol. 71, No. 6. pp. 968-972.
@article{326a8554ceed40269bc4d08b850b1cad,
title = "Correlation between body mass index and leucopenia after administration of valganciclovir for cytomegalovirus infection in Chinese cardiac recipients",
abstract = "Background: Valganciclovir (VGC) has recently been proved efficacious for the prophylaxis and treatment of cytomegalovirus (CMV) infection in transplant recipients. Leucopenia is a troublesome complication of VGC but the possible risk factors are unknown. Methods and Results: Once a cardiac recipient's quantitative real-time CMV-polymerase chain reaction result showed positive, VGC was administered for 3 months. The 61 cardiac recipients enrolled in this study were divided into 2 groups: non-leucopenia group (n=29) and leucopenia group (n=32). The white blood cell (WBC) counts in the leucopenia group dropped approximately 55.6{\%} in the first month after VGC therapy (pre-VGC WBC count: 5,544 cells/mm3 vs post-VGC WBC count: 2,460 cells/mm3, p<0.0001). The most significant difference between the 2 groups was body mass index (BMI, 23.04 vs 25.84, p=0.008), which was the impact factor of VGC-induced leucopenia. Conclusion: Severe leucopenia may develop after VGC therapy in Chinese cardiac recipients, especially those with lower BMI.",
keywords = "Cardiac transplant, Cytomegalovirus, Leucopenia, Valganciclovir",
author = "Chen, {I. Ming} and Chang, {Hsiao Huang} and Hsu, {Chiao Po} and Lai, {Shiau Ting} and Hsieh, {Yuan Chen} and Shih, {Chun Che}",
year = "2007",
month = "6",
day = "4",
doi = "10.1253/circj.71.968",
language = "English",
volume = "71",
pages = "968--972",
journal = "Circulation Journal",
issn = "1346-9843",
publisher = "Japanese Circulation Society",
number = "6",

}

TY - JOUR

T1 - Correlation between body mass index and leucopenia after administration of valganciclovir for cytomegalovirus infection in Chinese cardiac recipients

AU - Chen, I. Ming

AU - Chang, Hsiao Huang

AU - Hsu, Chiao Po

AU - Lai, Shiau Ting

AU - Hsieh, Yuan Chen

AU - Shih, Chun Che

PY - 2007/6/4

Y1 - 2007/6/4

N2 - Background: Valganciclovir (VGC) has recently been proved efficacious for the prophylaxis and treatment of cytomegalovirus (CMV) infection in transplant recipients. Leucopenia is a troublesome complication of VGC but the possible risk factors are unknown. Methods and Results: Once a cardiac recipient's quantitative real-time CMV-polymerase chain reaction result showed positive, VGC was administered for 3 months. The 61 cardiac recipients enrolled in this study were divided into 2 groups: non-leucopenia group (n=29) and leucopenia group (n=32). The white blood cell (WBC) counts in the leucopenia group dropped approximately 55.6% in the first month after VGC therapy (pre-VGC WBC count: 5,544 cells/mm3 vs post-VGC WBC count: 2,460 cells/mm3, p<0.0001). The most significant difference between the 2 groups was body mass index (BMI, 23.04 vs 25.84, p=0.008), which was the impact factor of VGC-induced leucopenia. Conclusion: Severe leucopenia may develop after VGC therapy in Chinese cardiac recipients, especially those with lower BMI.

AB - Background: Valganciclovir (VGC) has recently been proved efficacious for the prophylaxis and treatment of cytomegalovirus (CMV) infection in transplant recipients. Leucopenia is a troublesome complication of VGC but the possible risk factors are unknown. Methods and Results: Once a cardiac recipient's quantitative real-time CMV-polymerase chain reaction result showed positive, VGC was administered for 3 months. The 61 cardiac recipients enrolled in this study were divided into 2 groups: non-leucopenia group (n=29) and leucopenia group (n=32). The white blood cell (WBC) counts in the leucopenia group dropped approximately 55.6% in the first month after VGC therapy (pre-VGC WBC count: 5,544 cells/mm3 vs post-VGC WBC count: 2,460 cells/mm3, p<0.0001). The most significant difference between the 2 groups was body mass index (BMI, 23.04 vs 25.84, p=0.008), which was the impact factor of VGC-induced leucopenia. Conclusion: Severe leucopenia may develop after VGC therapy in Chinese cardiac recipients, especially those with lower BMI.

KW - Cardiac transplant

KW - Cytomegalovirus

KW - Leucopenia

KW - Valganciclovir

UR - http://www.scopus.com/inward/record.url?scp=34249667227&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249667227&partnerID=8YFLogxK

U2 - 10.1253/circj.71.968

DO - 10.1253/circj.71.968

M3 - Article

C2 - 17526998

AN - SCOPUS:34249667227

VL - 71

SP - 968

EP - 972

JO - Circulation Journal

JF - Circulation Journal

SN - 1346-9843

IS - 6

ER -